One Down

Eliminating Anti-Rejection Drug Improves Kidney Function in Transplant Recipients

| Nov 1, 2001

Researchers in the United Kingdom say that the anti-rejection medication sirolimus (Rapamune) allows for the early withdrawal of the anti-rejection drug cyclosporine in people who have had a kidney transplant.

Reporting their results in the September issue of Transplantation, researchers Robert W.G. Johnson and colleagues at the Manchester Royal Infirmary in Manchester, United Kingdom, randomized 525 kidney transplant patients at 57 transplant centers throughout Europe, Australia and Canada.

According to the Transplantation study, "Three months after transplantation, 430 patients were randomized either to have cyclosporine withdrawn and the [Rapamune] dose increased according to blood levels." The remainder of the patients remained on a "triple-drug therapy" of Rapamune, cyclosporine and steroids.

According to PR Newswire, 12 months after the kidney transplant, the cyclosporine-free patients showed significant improvement in kidney function. Hyper-tension, cyclo-sporine-associated kidney toxicity and excess uric acid in the blood were also significantly less frequent in the cyclosporine-free group.

The researchers note, "It will clearly be important to follow the patients in this study for several years to see if the observed benefits of this protocol translate into better clinical outcomes."

Click Here To View Or Post Comments

Categories: Kidney Care (Nephropathy), Medications, Medications Research, Research

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.